We determined that the mRNA expression of CASP3 and 7 was significantly upregulated after a 72 h treatment with exercise serum from advanced-stage PC patients (post- vs. pre-exercise serum: CASP3, 1.28 fold ± 0.05, p = 0.043; CASP 7, 1.12 fold ± 0.15, p = 0.0118; post-intervention serum exercise vs. control group: CASP3, p = 0.0034; CASP7, p = 0.0543, Figure 6A), as well as with EPS-conditioned myotube medium (CASP3, 1.22 fold ± 0.12, p = 0.0396; CASP 7, 1.37 fold ± 0.17, p = 0.0206). This evidence concerns the gene CASP7 and pachyonychia congenita.